Sci­en­tists are fi­nal­ly learn­ing how to de­sign pro­teins from scratch. Drug de­vel­op­ment may nev­er be the same

4 years ago
People
Discovery

Stay­ing in the back seat to Keytru­da, Bris­tol My­ers re­ports an­oth­er piv­otal set­back in urothe­lial can­cer

4 years ago
R&D
Pharma

Seek­ing a come-from-be­hind win, Eli Lil­ly lands big ap­proval for next-gen di­a­betes drug

4 years ago
Pharma
FDA+

Or­p­hazyme agrees to sell it­self, and its 'pipeline-in-a-prod­uct,' to Kem­Pharm

4 years ago
Deals

Clay Sie­gall re­signs from Seagen amid in­ves­ti­ga­tion in­to do­mes­tic vi­o­lence claims

4 years ago
People

With $270M in new funds, Shankar Ra­maswamy looks be­yond Roivant in scal­ing his gene ther­a­py 'con­sol­i­dat­ed en­gine'

4 years ago
Financing
Startups

Pfiz­er's $11.6B wa­ger; TIG­IT im­plo­sion; An un­usu­al phar­ma-biotech pact; In­side a16z's vi­sion to re­shape biotech; and ...

4 years ago
Weekly

Roche chair­man Christoph Franz of­fers glint of hope af­ter tiragolum­ab fail — re­port

4 years ago
Pharma

J&J’s ‘Texas two-step’ talc bank­rupt­cy case heads back to ap­peals court

4 years ago
Pharma
Law

Strik­ing mu­rals in US cities high­light Hori­zon and Arthri­tis Foun­da­tion col­lab for gout aware­ness

4 years ago
Pharma
Marketing

UK gener­ics mak­er shut­ters, elim­i­nat­ing 1,000 jobs

4 years ago
Pharma
Manufacturing

Is­rael sues Te­va over block­buster MS drug, seek­ing $100M in roy­al­ty pay — re­port

4 years ago
Pharma
Law

Roche ends a bad, no good, plain lousy week with a $0 co-pay copy­cat stalk­ing one of its block­busters

4 years ago
Pharma

Bris­tol My­ers Squibb strikes deal to sell NY site to South Ko­re­an con­glom­er­ate — but it's keep­ing qui­et on the ...

4 years ago
Deals
Pharma

BioFron­tera bows bold im­agery web­sites amid Q1 sales gains in der­ma­tol­ogy

4 years ago
Pharma
Marketing

Ab­b­Vie un­veils lat­est round of im­munol­o­gy schol­ar­ships for pa­tients with chron­ic dis­ease

4 years ago
Pharma

Af­ter ramp­ing up its vac­cine pro­duc­tion in South Africa, As­pen yet to re­ceive a sin­gle or­der

4 years ago
Pharma
Manufacturing

NFL leg­end Brett Favre named in Mis­sis­sip­pi tri­al over mis­ap­pro­pri­at­ed wel­fare funds go­ing to con­cus­sion biotech

4 years ago
People
Law

Roche's TIG­IT fall­out caus­es GSK and iTeos to re-think their own I/O can­di­date

4 years ago
R&D
Pharma

Re­gen­eron did­n't want to 'bid against it­self' in Check­mate deal as five glob­al phar­mas de­clined to coun­terof­fer

4 years ago
Deals
Pharma

Scoop: Ar­cus CMO Kar­tik Kr­ish­nan left for new op­por­tu­ni­ty ahead of big TIG­IT read­out

4 years ago
People

Quash­ing block­buster hopes, FDA spurns UCB’s IL-17 drug for plaque pso­ri­a­sis

4 years ago
R&D
FDA+

FDA ap­proves oral for­mu­la­tion of old ALS drug, giv­ing pa­tients new treat­ment op­tion in sore­ly need­ed field

4 years ago
FDA+

Work­ing to right the ship, Bridge­Bio's Neil Ku­mar adds a $110M deal right on top of his cash haul from Bris­tol My­ers

4 years ago
Deals
Bioregnum
First page Previous page 531532533534535536537 Next page Last page
A service from the Financial Times